The Times Australia
Fisher and Paykel Appliances
The Times World News

.

What's available and how to get them

  • Written by Nial Wheate, Associate Professor of the Sydney Pharmacy School, University of Sydney
what's available and how to get them

With COVID case numbers expected to rise[1] in Australia over the coming weeks and months there is significant concern the numbers of severely sick patients may overwhelm hospitals.

Thankfully, over time we are learning more about COVID[2] and now have a range of medicines that are effective in treating it, including antivirals.

Which medicine a patient receives, if they even need one at all, will depend on the severity of their symptoms and whether they have any underlying health problems.

Read more: How are Australia and NZ managing the rising COVID winter wave – and is either getting it right?[3]

Here is what we have in our COVID arsenal

When the COVID pandemic began, we didn’t have any drugs to treat the virus. Instead, we had to rely on drugs that could treat COVID symptoms while the body healed itself.

Now we have a range of recommended COVID medicines[4] that are either antivirals or antibody-based drugs. These are suitable for both hospitalised and at-home patients and include lagevrio[5], remdesivir[6], paxlovid[7], evusheld[8] and sotrovimab[9].

In Australia, there are other antibody drugs available but they are not currently widely used. This includes ronapreve[10], which is less effective[11] against the omicron strain of the virus, and regkirona[12] which is still being explored in clinical trials[13].

Other drugs are also used for COVID but, again, they don’t treat the virus. Instead they are mostly used to reduce inflammation in the lungs.

These medicines have all been shown to work in human clinical trials and are either fully or provisionally approved by the Australian Therapeutic Goods Administration[14] for the treatment of COVID.

Each COVID medicine works in a different way. Evusheld and sotrovimab comprise antibody molecules that neutralise the virus and block its entry into human cells, whereas paxlovid works by stopping a key enzyme the virus needs to replicate. Both lagevrio and remdesivir work by getting incorporated into the virus’ genetic material and causing mutations to stop the virus from replicating.

Paxlovid and lagevrio come in tablet form while remdesivir, sotrovimab, and evusheld come as injections that need to be administered by a doctor.

older man sick in bed with tissue
Who you are and whether you are at home or in hospital will determine your treatment. Shutterstock[15]

Read more: Australia approves two new medicines in the fight against COVID. How can you get them and are they effective against Omicron?[16]

The right drug for the right patient

Clinical guidelines[17] direct health staff as to which drug they need to administer to each patient.

Most people who test positive for COVID will not need treatment with an antiviral drug, as current COVID variants tend to induce mild symptoms that can be managed with rest and isolation at home.

For some patients managing COVID at home, certain health factors mean their doctor will prescribe a COVID drug. This includes people who have a poor functioning immune system, those who are not vaccinated or are not up-to-date with vaccinations, and those who are at a high risk of severe disease.

These risk factors[18] include respiratory conditions such as asthma, cardiovascular diseases including high blood pressure, obesity, diabetes and kidney failure.

Where you’re treated

If a patient is sick enough to need hospitalisation, specialist doctors will decide if and what COVID drug to prescribe.

If a COVID drug is needed for an at-home patient both lagevrio and paxlovid are available on the Pharmaceutical Benefits Scheme (PBS)[19] for specific people[20] including those over 70, or those over 50 who have one of the risk factors mentioned earlier.

Immunocompromised people over the age of 18, and people who identify as Aboriginal or Torres Strait Islander origin who are over 30 and at high risk, are also eligible for PBS-subsidised lagevrio or paxlovid.

These drugs can be prescribed by a general practitioner (GP) and accessed through a local community pharmacy. If a patient is not able to see their GP in person, a COVID drug can be prescribed by booking a telehealth appointment[21] with a doctor. The drug can then be delivered to their home from their local pharmacy. Importantly, these drugs must be started within five days of symptom onset[22].

In some instances an at-home COVID patient may require an injection-only drug such as remdesivir or evusheld, which are only available through the patient’s local hospital network. Sotrovimab is another COVID drug that is only administered in healthcare facilities. This is because patients need to be monitored after they receive the infusion. General practitioners will refer their patients to a local hospital for these treatments.

Read more: I have mild COVID – should I take the antiviral Paxlovid?[23]

What about side effects?

All medicines have side effects, even common medications like paracetamol and aspirin.

If patients do experience side effects, these are likely to be specific to the drug being taken. Some of the possible side effects of lagevrio[24] include mild to moderate diarrhoea, nausea and dizziness in less than 2% of those trialled.

For paxlovid[25], side effects can include changes in taste, diarrhoea, headache, and vomiting. Serious side effects, which affect fewer than 2% of patients[26], include liver problems which can cause prolonged nausea or vomiting, loss of appetite, stomach pain, yellowing eyes or skin, and dark urine[27].

Some of the side effects of remdesivir[28] include rash, sweating, fever, shortness of breath, swelling, changes in blood pressure or heart rate, nausea, and shivering.

Patients who experience side effects while taking a COVID drug should see their doctor if they are concerned. If a patient experiences any severe side effects, such as signs of liver problems, then they should call their doctor immediately or go straight to their local hospital.

References

  1. ^ COVID case numbers expected to rise (www.abc.net.au)
  2. ^ we are learning more about COVID (theconversation.com)
  3. ^ How are Australia and NZ managing the rising COVID winter wave – and is either getting it right? (theconversation.com)
  4. ^ recommended COVID medicines (www.health.gov.au)
  5. ^ lagevrio (www.nps.org.au)
  6. ^ remdesivir (www.nps.org.au)
  7. ^ paxlovid (www.tga.gov.au)
  8. ^ evusheld (www.health.gov.au)
  9. ^ sotrovimab (www.fda.gov)
  10. ^ ronapreve (www.tga.gov.au)
  11. ^ less effective (covid19evidence.net.au)
  12. ^ regkirona (www.tga.gov.au)
  13. ^ clinical trials (app.magicapp.org)
  14. ^ Therapeutic Goods Administration (tga.gov.au)
  15. ^ Shutterstock (image.shutterstock.com)
  16. ^ Australia approves two new medicines in the fight against COVID. How can you get them and are they effective against Omicron? (theconversation.com)
  17. ^ Clinical guidelines (covid19evidence.net.au)
  18. ^ risk factors (www.health.gov.au)
  19. ^ lagevrio and paxlovid are available on the Pharmaceutical Benefits Scheme (PBS) (www.health.gov.au)
  20. ^ specific people (www.pbs.gov.au)
  21. ^ telehealth appointment (www.health.gov.au)
  22. ^ five days of symptom onset (www.tga.gov.au)
  23. ^ I have mild COVID – should I take the antiviral Paxlovid? (theconversation.com)
  24. ^ lagevrio (www.nps.org.au)
  25. ^ paxlovid (www.nps.org.au)
  26. ^ fewer than 2% of patients (www.tga.gov.au)
  27. ^ dark urine (www.webmd.com)
  28. ^ side effects of remdesivir (www.ebs.tga.gov.au)

Read more https://theconversation.com/covid-drugs-in-australia-whats-available-and-how-to-get-them-186907

Times Magazine

This Christmas, Give the Navman Gift That Never Stops Giving – Safety

Protect your loved one’s drives with a Navman Dash Cam.  This Christmas don’t just give – prote...

Yoto now available in Kmart and The Memo, bringing screen-free storytelling to Australian families

Yoto, the kids’ audio platform inspiring creativity and imagination around the world, has launched i...

Kool Car Hire

Turn Your Four-Wheeled Showstopper into Profit (and Stardom) Have you ever found yourself stand...

EV ‘charging deserts’ in regional Australia are slowing the shift to clean transport

If you live in a big city, finding a charger for your electric vehicle (EV) isn’t hard. But driv...

How to Reduce Eye Strain When Using an Extra Screen

Many professionals say two screens are better than one. And they're not wrong! A second screen mak...

Is AI really coming for our jobs and wages? Past predictions of a ‘robot apocalypse’ offer some clues

The robots were taking our jobs – or so we were told over a decade ago. The same warnings are ...

The Times Features

What’s been happening on the Australian stock market today

What moved, why it moved and what to watch going forward. 📉 Market overview The benchmark S&am...

The NDIS shifts almost $27m a year in mental health costs alone, our new study suggests

The National Disability Insurance Scheme (NDIS) was set up in 2013[1] to help Australians with...

Why Australia Is Ditching “Gym Hop Culture” — And Choosing Fitstop Instead

As Australians rethink what fitness actually means going into the new year, a clear shift is emergin...

Everyday Radiance: Bevilles’ Timeless Take on Versatile Jewellery

There’s an undeniable magic in contrast — the way gold catches the light while silver cools it down...

From The Stage to Spotify, Stanhope singer Alyssa Delpopolo Reveals Her Meteoric Rise

When local singer Alyssa Delpopolo was crowned winner of The Voice last week, the cheers were louder...

How healthy are the hundreds of confectionery options and soft drinks

Walk into any big Australian supermarket and the first thing that hits you isn’t the smell of fr...

The Top Six Issues Australians Are Thinking About Today

Australia in 2025 is navigating one of the most unsettled periods in recent memory. Economic pre...

How Net Zero Will Adversely Change How We Live — and Why the Coalition’s Abandonment of That Aspiration Could Be Beneficial

The drive toward net zero emissions by 2050 has become one of the most defining political, socia...

Menulog is closing in Australia. Could food delivery soon cost more?

It’s been a rocky road for Australia’s food delivery sector. Over the past decade, major platfor...